- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02423850
Three-dimensional Measurements of Diabetic Foot Ulcers
Three-dimensional Measurements for Monitoring Wound Healing of Diabetic Foot Ulcers
Diabetic foot ulcers constitute an increasing health problem in Denmark concurrent with an ageing population and an increase in diabetes prevalence. Diabetic foot ulcers belong to the most serious and costly complications. Several studies have found that the size and depth of the ulcer is one of the major etiologic factors for delayed healing. Wound measurement is important in the monitoring of the wound healing process. For the last decade different 3D (three-dimensional) techniques for measuring wounds have been proposed in order to measure wound volume, but none of the technologies have been widely used. A 3D Wound Assessment Monitor (WAM) camera has been developed, which is able to measure wound size in 3D and to assess wound characteristics.
The investigators hypothesize that three-dimensional measurements of diabetic foot ulcers are feasible in the assessment of wound healing. A prospective cohort study is conducted in which newly admitted patients with a diabetic foot ulcer are included at the first visit at the multidisciplinary clinic. The patients are followed for one year or until complete wound healing, amputation or death. The four wound measurements: 2D area, 3D area, perimeter and volume are measured using the 3D-WAM camera with frequent intervals. Patient anthropometrics and wound data are collected during the study and correlated to the wound healing.
Study Overview
Status
Intervention / Treatment
Detailed Description
Method
Newly admitted patients with a diabetic foot ulcer are included at the first visit in the multidisciplinary clinic. The data mentioned below are collected at the first visit and the following examinations are performed including 3D photos. The wound size (2D area, 3D area, perimeter and volume) are estimated from the photos using the 3D-WAM camera. The wound examination is repeated after 2, 4, 8, 12, 24, 36 and 52 weeks or until healing of the wound. The wound healing is estimated using changes in wound size per time unit. Patients are treated by standard ulcer treatment methods and are unaffected by the project per se. During the trial the different methods of treatment are noted including changes from initial treatment. The variables will be quantified after one year depending on time to heal, establishment of a chronic ulcer (non-healing after one year) or an amputation has been performed.
At baseline the following patient data will be collected:
- Demographic data: gender, age
- Smoking habits
- Time period between onset of wound to first visit in the multidisciplinary clinic
- Body Mass Index
- Comorbidity using Charlson Comorbidity Index score
- Type of diabetes, duration of diabetes
- Diabetic complications including retinopathy, albuminuria, coronary heart diseases and neuropathy
The following examinations will be performed at baseline:
- Blood pressure measurement
- Peripheral blood pressure
- Examination for neuropathy using monofilament
- Blood samples from patients with a diabetic foot ulcer
The clinical examination of the ulcer are performed at baseline and after 2, 4, 8, 12, 24, 36 and 52 weeks or until wound healing:
- Size of wound (2D area, 3D area, perimeter, volume) measured using the 3D-WAM camera
- Size of wound in 2D area using the digital imaging method with the software ImageJ
- Location of the ulcer
- Classification of ulcer: granulation, necrosis, epithelialisation
- Secretory potential
- Foot deformity
- Bone affection - if osteitis is suspected an x-ray is taken
- Signs of infection
The different types of ulcer treatment is registered for every ulcer:
- Type of bandage
- Antibiotics (local, systemic)
- Revision (method, frequency),
- Surgery
Effect variables
- Wound 2D area, 3D area, perimeter and volume
- Variation in 2D and 3D area measurements during the study period
- Percentage change in wound size after 2, 4, 8, 12, 24, 36 and 52 weeks
Endpoints
- Wound healing
- Amputations
- Chronic wound (non-healing after 1 year)
- Death
Significance
This project seeks to clarify whether 3D photos of wounds will provide accurate structural measures to illuminate the background for delayed ulcer healing, and thereby to create platform for a more evidence based treatment algorithm.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Odense, Denmark, 5000
- University Centre of Wound Healing, Odense University Hospital (OUH)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Newly admitted patients with diabetic foot ulcers
- 18 years or older
Exclusion Criteria:
- Superficial wound (less than 5x5 mm with no substantial loss of subcutaneous tissue)
- Non-compliance (dementia, mental disorders)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Diabetic foot ulcers
Newly referred patients with diabetic foot ulcers from the multidisciplinary clinic: University Centre for Wound healing, Odense University Hospital, Denmark.
|
Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound healing change quantified using the 3D-WAM camera
Time Frame: Photos are taken at week 0, 2, 4, 8, 12, 24, 36 and 52 weeks
|
The 3D wound measurements at week 2, 4, 8, 12, 24, 36 and 52 are compared to the baseline measurement at week 0.
|
Photos are taken at week 0, 2, 4, 8, 12, 24, 36 and 52 weeks
|
Wound healing change quantified using digital imaging method
Time Frame: Photos are taken at week 0, 2, 4, 8, 12, 24, 36 and 52 weeks
|
The 2D wound measurements at week 2, 4, 8, 12, 24, 36 and 52 are compared to the baseline measurement at week 0.
|
Photos are taken at week 0, 2, 4, 8, 12, 24, 36 and 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The variability in 2D area and 3D area measurements
Time Frame: Photos are taken at week 0, 2, 4, 8, 12, 24, 36 and 52 weeks
|
The variability in 2D area (digital imaging method) and 3D area wound measurements (3D-WAM camera) at week 0, 2, 4, 8, 12, 24, 36 and 52 are compared
|
Photos are taken at week 0, 2, 4, 8, 12, 24, 36 and 52 weeks
|
Diabetes type is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
Type 1 and 2
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
Diabetes duration is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
In years
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
BMI (kg/m2) is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
kg/m2
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
Charlson index score is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
In groups
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
HbA1c is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
mmol/mol
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
Ischemia is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
Ischemia is defined by ankle pressure below 70 mmHg and/or toe pressure below 45 mmHg
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
Neuropathy is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
Neuropathy is measured by Semmes Weinstein monofilament examination
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
Wound duration is compared to outcome of the wound
Time Frame: Baseline until healing, amputation or chronic wound (52 weeks)
|
In weeks
|
Baseline until healing, amputation or chronic wound (52 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life (Questionaires) using 36-Item Short Form Survey (SF-36) is compared to outcome of the wound
Time Frame: Baseline, 24 and 52 weeks
|
The higher the score the less disability
|
Baseline, 24 and 52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Knud Yderstræde, MD, PhD, Department of Endocrinology, Odense University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Skin Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetic Angiopathies
- Leg Ulcer
- Skin Ulcer
- Diabetic Neuropathies
- Foot Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Foot
- Foot Ulcer
- Diabetes Mellitus, Type 1
- Diabetes Complications
Other Study ID Numbers
- OUH3D02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
HighTide Biopharma Pty LtdRecruitingT2DM (Type 2 Diabetes Mellitus)China
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on 3D Wound Assessment Monitor (WAM) camera
-
Croydon Health Services NHS TrustCompletedAnal Sphincter Injury | Obstetric Trauma | Perineal Infection | Perineum; InjuryUnited Kingdom